Should of bought RIOT too- Riot Platforms, Inc. (RIOT) NasdaqCM - NasdaqCM Real Time Price. 9.67+0.80(+9.02%)<---------- At close: October 23 04:00PM EDT 11.05+1.38(+14.27%)<----------------- Pre-Market:07:29AM EDT
GBA GUMMY ignites Sector-! //// TeraWulf Inc. (WULF) NasdaqCM - NasdaqCM Real Time Price. 1.2000+0.1000(+9.09%) At close: October 23 04:00PM EDT 1.3700+0.17(+14.17%) <------------------ THANK YOU PAPA~ Pre-Market:07:27AM EDT
What's the other gummy? I am looking for a Van pick. Evolv Technologies Holdings, Inc. (EVLV) NasdaqCM - NasdaqCM Real Time Price. 3.9400+0.1300(+3.41%) At close: October 23 04:00PM EDT 3.8300-0.11(-2.79%) After hours:Oct 23, 07:28PM EDT
SECTOR-WIDE...... TY GBA! WHAT A CALL! This year: First to nail AI // First to get into and out of China // First to call out Crypto rally!!!! GBAGBAGBAGBAGBAGBA- #1
GBA Target $1.35 ZeroFox Holdings, Inc. (ZFOX) NasdaqGM - NasdaqGM Real Time Price. 0.6949+0.0210(+3.12%) At close: October 23 04:00PM EDT 0.7200+0.03(+3.61%)<--------------- Pre-Market:07:41AM EDT
CymaBay Therapeutics, Inc. (CBAY) GO GO GO!!!!!! NasdaqGS - NasdaqGS Real Time Price. 14.69+1.08(+7.94%) At close: October 23 04:00PM EDT 15.13+0.44(+3.00%)<------------------ Pre-Market:08:00AM EDT
Why CymaBay Therapeutics Stock Rocketed Nearly 8% Higher Today- A GBA Upgrade led to....... KEY POINTS The leading drug candidate in the biotech's pipeline scored another win. Seladelpar's existing Breakthrough Therapy Designation was expanded by the FDA. CymaBay had originally earned Breakthrough Therapy Designation for seladelpar in 2019, on the back of encouraging preliminary results from a phase 2 clinical trial. These findings indicated that the drug substantially reduced serum alkaline phosphatase, an enzyme that at elevated levels can indicate liver disease. Will seladelpar soon be approved? While the FDA's latest ruling on seladelpar is neither an authorization nor an approval, it was a highly encouraging signal that the drug is well on its way toward getting the FDA's green light. If and when it does, it's likely to be a popular treatment, assuming that it's marketed effectively.